DEFINITIVE CONTRACT
Active75F40126C00062
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$693.8K
obligated · signed 3 months ago
CONSULTATION AND PEER REVIEW FOR THE DIVISION OF RISK ASSESSMENT AND PRIORITIZATION
Performance timeline
Start
Jul 13, 2026
End
Jul 12, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Jul 12, 2027
VERSAR, INC.
Contract 75F40126C00062
UEI
KTERFRZBVP66
Parent Company
VERSAR, INC.
Capabilities & Certifications
Headquarters Location
Congressional District: 98
Current Obligation
$693,828
Base + Exercised Options
$693,828
Total Ceiling Value
$693,828
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES
PSC
SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA
Place of Performance
Congressional District: 04
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.